{"id":"https://openalex.org/W2462880477","doi":null,"title":"Original Article Using Pharmacoeconomic Modelling to Determine Value-Based Pricing for New Pharmaceuticals in Malaysia","display_name":"Original Article Using Pharmacoeconomic Modelling to Determine Value-Based Pricing for New Pharmaceuticals in Malaysia","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2462880477","mag":"2462880477"},"language":"en","primary_location":{"id":"mag:2462880477","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Sangameshwar_Mahagaonkar/publication/224966870_Using_pharmacoeconomic_modelling_to_determine_value-based_pricing_for_new_pharmaceuticals_in_Malaysia/links/0046352695b9709530000000.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2462880477"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078386925","display_name":"George Dranitsaris","orcid":"https://orcid.org/0000-0002-1637-3122","observed_orcids":["https://orcid.org/0000-0002-1637-3122"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"George Dranitsaris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040666262","display_name":"Martie S. Lubbe","orcid":"https://orcid.org/0000-0001-7611-6171","observed_orcids":["https://orcid.org/0000-0001-7611-6171"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martie S. Lubbe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5055881200","display_name":"Nitin N. Sriramanakoppa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nitin N. Sriramanakoppa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":92},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/value-based-pricing","display_name":"value-based pricing","score":0.9300000071525574},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9150000214576721},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/cost-effectiveness-threshold","display_name":"cost-effectiveness threshold","score":0.6370000243186951},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7710000276565552},{"id":"https://openalex.org/keywords/decision-analysis","display_name":"decision analysis","score":0.5299999713897705},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.5090000033378601},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5899999737739563},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5550000071525574},{"id":"https://openalex.org/keywords/oncology-nurses","display_name":"oncology nurses","score":0.7070000171661377},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.46799999475479126},{"id":"https://openalex.org/keywords/malaysia","display_name":"Malaysia","score":0.7020000219345093}],"concepts":[{"id":"https://openalex.org/C2776291640","wikidata":"https://www.wikidata.org/wiki/Q2912517","display_name":"Value (mathematics)","level":2,"score":0.533611536026001},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.5247278809547424},{"id":"https://openalex.org/C162118730","wikidata":"https://www.wikidata.org/wiki/Q1128453","display_name":"Actuarial science","level":1,"score":0.465295672416687},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.35289466381073},{"id":"https://openalex.org/C149782125","wikidata":"https://www.wikidata.org/wiki/Q160039","display_name":"Econometrics","level":1,"score":0.33673542737960815},{"id":"https://openalex.org/C539667460","wikidata":"https://www.wikidata.org/wiki/Q2414942","display_name":"Management science","level":1,"score":0.3239510953426361},{"id":"https://openalex.org/C119857082","wikidata":"https://www.wikidata.org/wiki/Q2539","display_name":"Machine learning","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2462880477","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Sangameshwar_Mahagaonkar/publication/224966870_Using_pharmacoeconomic_modelling_to_determine_value-based_pricing_for_new_pharmaceuticals_in_Malaysia/links/0046352695b9709530000000.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1554701668","https://openalex.org/W1830444419","https://openalex.org/W1969663710","https://openalex.org/W1990076987","https://openalex.org/W2032689844","https://openalex.org/W2043304606","https://openalex.org/W2057586884","https://openalex.org/W2083774542","https://openalex.org/W2094145886","https://openalex.org/W2110046944","https://openalex.org/W2115445021","https://openalex.org/W2128403792","https://openalex.org/W2128447158","https://openalex.org/W2133399075","https://openalex.org/W2143743735","https://openalex.org/W2158888710","https://openalex.org/W2164654252","https://openalex.org/W2336740718"],"related_works":["https://openalex.org/W2408931764","https://openalex.org/W2076466508","https://openalex.org/W1708223485","https://openalex.org/W2113487348","https://openalex.org/W2115805885","https://openalex.org/W2042138938","https://openalex.org/W2890610786","https://openalex.org/W2746751212","https://openalex.org/W2159989659"],"abstract_inverted_index":{"Background:\ufffdDecisionanalysis\ufffd(DA)\ufffdiscommonlyusedtoperformeconomicevaluationsof\ufffd":[0],"newpharmaceuticals.\ufffdUsingmultiplesofMalaysia'spercapita\ufffd2010\ufffdgrossdomesticproduct\ufffd(GDP)\ufffd":[1],"asthethresholdforeconomicvalueassuggestedbytheWorldHealthOrganization\ufffd(WHO),\ufffdDAwas\ufffd":[2],"usedtoestimateapriceperdoseforbevacizumab,\ufffdadrugthatprovidesa\ufffd1.4-monthsurvivalbenefit\ufffd":[3],"inpatientswithmetastaticcolorectalcancer\ufffd(mCRC).":[4],"\ufffd":[5,16],"Methods:":[6],"Adecisionmodelwasdevelopedtosimulateprogression-freeandoverallsurvival\ufffd":[7],"inmCRCpatientsreceivingchemotherapywithandwithoutbevacizumab.\ufffdCostsforchemotherapy\ufffd":[8],"andmanagementofsideeffectswereobtainedfrompublicandprivatehospitalsinMalaysia.\ufffdUtility\ufffd":[9],"estimates,\ufffd":[10],"measuredasquality-adjustedlifeyears\ufffd":[11],"(QALYs),\ufffd":[12],"weredeterminedbyinterviewing\ufffd\ufffd":[13],"24\ufffdoncologynursesusingthetimetrade-offtechnique.\ufffdThepriceperdosewasthenestimatedusing\ufffd":[14],"atargetthresholdofUS$44\ufffd400\ufffdperQALYgained,\ufffdwhichis\ufffd3\ufffdtimestheMalaysianpercapitaGDP.":[15],"Results:":[17],"Acost-effectivepriceforbevacizumabcouldnotbedeterminedbecausethesurvival\ufffd":[18],"benefitprovidedwasinsufficientAccordingtotheWHOcriteria,\ufffdifthedrugwasabletoimprove\ufffd":[19],"survivalfrom\ufffd1.4\ufffdto\ufffd3\ufffdor\ufffd6\ufffdmonths,\ufffdthepriceperdosewouldbe\ufffd$567\ufffdand\ufffd$1258,\ufffdrespectively.":[20],"Conclusion:":[21],"Theuseofdecisionmodellingforestimatingdrugpricingisapowerfultechnique\ufffd":[22],"toensurevalueformoney.\ufffd":[23],"Suchinformationisofvaluetodrugmanufacturersandformulary\ufffd":[24],"committeesbecauseitfacilitatesnegotiationsforvalue-basedpricinginagivenjurisdiction.":[25]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2462880477","counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-07-22T00:00:00"}
